Sofosbuvir/Velpatasvir (Epclusa®)

Assessment Status Rapid review complete
HTA ID -
Drug Sofosbuvir/Velpatasvir
Brand Epclusa®
Indication For the treatment of chronic hepatitis C virus (HCV) infection in adults
Assessment Process
Rapid review commissioned 12/07/2016
Rapid review completed 23/08/2016
Rapid review outcome Full pharmacoeconomic evaluation not recommended for HCV genotype 3 infection